Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Fig. 3

Observed versus expected use of therapies by region. Observed number of patients (blue) who received the indicated drug as first-line of therapy and number of patients expected (red) to have received the drug as first-line, by geographic division, in 2014. Expected numbers are calculated under the assumption of independence between geographic division and focus drug and account for the fact that there are differing numbers of patients enrolled in different regions. The category “Other” includes sipuleucel-T, radium-223, and cabazitaxel. NE, New England; MA, Middle Atlantic; SA, South Atlantic; ENC, East North Central; WNC, West North Central; WSC, West South Central; M, Mountain; PAC, Pacific; UNK, Unknown. States within each geographic region: New England: Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Massachusetts. Middle Atlantic: New Jersey, New York, Pennsylvania. South Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia. East North Central: Illinois, Indiana, Michigan, Ohio, Wisconsin. East South Central: Alabama, Kentucky, Mississippi, Tennessee. West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota. West South Central: Arkansas, Louisiana, Oklahoma, and Texas. Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming. Pacific: Alaska, California, Hawaii, Oregon, Washington

Back to article page
\